TransCode's TTX-MC138 To Enter Phase 2a Trial As Part Of Quantum Leap PRE-I-SPY Platform

TransCode Therapeutics and Quantum Leap Healthcare Collaborative will test TTX-MC138 in a Phase 2a dose-expansion trial within the PRE-I-SPY platform after Phase 1a results met the primary safety endpoint and established a recommended Phase 2 dose. TTX-MC138, a first-in-class inhibitor of microRNA-10b linked to metastatic progression, will enroll up to 45 ctDNA-positive colorectal cancer patients with minimal residual disease after curative-intent therapy, with enrollment planned to begin in H1 2026 to evaluate biological and clinical activity in the MRD setting. The program targets the unmet need of eradicating micrometastatic disease and could meaningfully affect long-term outcomes if successful; RNAZ shares traded at $10.42 (up 20.74% at close) then moved to $9.92 in pre-market (down 4.80%).

Analysis

TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to advance TTX-MC138 into a Phase 2a dose-expansion trial within the PRE-I-SPY platform, following positive Phase 1 readouts. TTX-MC138 is described as a first-in-class inhibitor of microRNA-10b, a target linked to metastatic progression, and the Phase 1a study met its primary safety endpoint while establishing a recommended Phase 2 dose.

The planned Phase 2a will enroll up to 45 ctDNA-positive colorectal cancer patients with minimal residual disease after curative-intent therapy, with initiation expected in H1 2026; the MRD setting is positioned by the company as the highest-opportunity context to test biological and clinical activity. A successful signal here—particularly ctDNA clearance or consistent pharmacodynamic effects—would materially de-risk the program and support valuation upside given the unmet need in micrometastatic disease.

Market reaction has been volatile: RNAZ closed at $10.42 (+20.74%) then moved to $9.92 (-4.80%) pre-market, and external sentiment metrics are moderately positive with modest market-impact scoring. Key risks are typical early-stage binaries: small sample size (n≤45), long timelines to readout, and execution risk on enrollment and biomarker endpoints, implying significant upside if positive but high downside if not.

Key Decisions for Investors

• Consider a small, speculative position given Phase 1 safety and the collaboration, but avoid material exposure until Phase 2a demonstrates biological activity
• Monitor trial operational milestones closely—actual start in H1 2026, enrollment pace for the 45-patient MRD cohort, and interim ctDNA or PD signals—as primary de‑risking triggers
• Apply active risk management (position limits or hedges) because the stock has shown high intraday volatility (closed $10.42 up 20.74% then pre-market $9.92 down 4.80%) and clinical outcomes are binary
• If Phase 2a yields clear biological activity or reproducible MRD clearance, reassess to increase allocation; absent such signals, prioritize capital toward later-stage programs with demonstrable efficacy